Trial Profile
A Phase II Clinical Study on Efficacy of Palbociclib in Advanced Acral Melanoma With Cell Cycle Gene Aberrations
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Aug 2022
Price :
$35
*
At a glance
- Drugs Palbociclib (Primary)
- Indications Acral lentiginous melanoma; Malignant melanoma
- Focus Therapeutic Use
- 23 Mar 2021 Results published in the European Journal of Cancer
- 08 Jun 2019 Status changed from not yet recruiting to active no longer recruiting.
- 04 Jun 2019 Primary endpoint (Overall response rate) has been met as per results presented at 55th Annual Meeting of the American Society of Clinical Oncology.